Paris (ots/PRNewswire) – - Findings Consistent with Known Post-Prandial Effect of Lyxumia Supporting Combination with Basal Insulin – Sanofi announced today new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia(R) (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). These […]
Trending Articles
More Pages to Explore .....